NASDAQ:AUPH Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis $16.56 +0.42 (+2.60%) Closing price 11/3/2026 04:00 PM EasternExtended Trading$16.31 -0.25 (-1.52%) As of 11/3/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AUPH alerts:Sign Up Key Stats Today's Range$16.13▼$16.7350-Day Range$15.69▼$17.3652-Week Range$13.33▼$19.25Volume1.18 million shsAverage Volume822,171 shsMarket Capitalization$2.22 billionP/E Ratio7.23Dividend YieldN/APrice Target$18.25Consensus RatingModerate Buy Company Overview Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s principal product is Lupkynis (voclosporin), an oral calcineurin inhibitor used in combination with other immunosuppressive therapies to treat adults with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus. Voclosporin was approved by the U.S. Food and Drug Administration in 2021, making Lupkynis the first oral therapy specifically approved in the United States for adult patients with active lupus nephritis. Aurinia’s activities include commercial operations, medical education, patient support, and ongoing research related to autoimmune and kidney diseases. Aurinia was founded in Canada and has served patients and healthcare providers primarily in the United States, while also pursuing international commercial and development opportunities through partnerships. The company is headquartered in Victoria, British Columbia, and maintains operations supporting the development and commercialization of its therapies.AI Generated. May Contain Errors. Read More Aurinia Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreAUPH MarketRank™: 3.14599312351 of 5 starsAurinia Pharmaceuticals scored higher than 63% of companies evaluated by MarketBeat, and ranked 225th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingModerate Buy Consensus RatingAurinia Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 3 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialAurinia Pharmaceuticals has a consensus price target of $18.25, representing about 10.2% upside from its current price of $16.56.Amount of Analyst CoverageAurinia Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Aurinia Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth14.29% Earnings GrowthEarnings for Aurinia Pharmaceuticals are expected to grow by 14.29% in the coming year, from $0.91 to $1.04 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aurinia Pharmaceuticals is 7.23, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.53.Price to Earnings Ratio vs. SectorThe P/E ratio of Aurinia Pharmaceuticals is 7.23, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.90.Price to Book Value per Share RatioAurinia Pharmaceuticals has a P/B Ratio of 3.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.53% of the float of Aurinia Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAurinia Pharmaceuticals has a short interest ratio ("days to cover") of 8.96.Change versus previous monthShort interest in Aurinia Pharmaceuticals has recently decreased by 1.77%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAurinia Pharmaceuticals does not currently pay a dividend.Dividend GrowthAurinia Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.67 News SentimentAurinia Pharmaceuticals has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Aurinia Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for AUPH on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aurinia Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.40% of the stock of Aurinia Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions36.83% of the stock of Aurinia Pharmaceuticals is held by institutions.Read more about Aurinia Pharmaceuticals' insider trading history. Receive AUPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AUPH Stock News HeadlinesAurinia Pharmaceuticals (NASDAQ:AUPH) Stock Gets Price Target Bump from Royal Bank Of Canada1 hour ago | americanbankingnews.comRBC Raises Price Target on Aurinia Pharmaceuticals to $18 From $16, Keeps Sector Perform, Speculative RiskNovember 2 at 4:03 PM | marketscreener.comMThe most dangerous moment in a financial crisisDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008. | Weiss Ratings (Ad)Aurinia Pharmaceuticals Inc. Raises Earnings Guidance for the Full Fiscal Year 2026October 30, 2026 | marketscreener.comMAurinia Skids on ResultsOctober 30, 2026 | baystreet.caEarnings Flash (AUPH) Aurinia Pharmaceuticals Inc. Reports Q3 Revenue $83.7M, vs. FactSet Est of $83.6MOctober 30, 2026 | marketscreener.comMAurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business ProgressOctober 30, 2026 | financialpost.comFWhy Aurinia Pharmaceuticals (AUPH) is a top growth stock for the long termOctober 26, 2026 | msn.comSee More Headlines AUPH Stock Analysis - Frequently Asked Questions How have AUPH shares performed this year? Aurinia Pharmaceuticals' stock was trading at $15.95 at the beginning of the year. Since then, AUPH stock has increased by 3.8% and is now trading at $16.56. How were Aurinia Pharmaceuticals' earnings last quarter? Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) released its earnings results on Friday, October, 30th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.01. The biotechnology company had revenue of $83.70 million for the quarter, compared to analyst estimates of $83.61 million. Aurinia Pharmaceuticals had a net margin of 97.68% and a trailing twelve-month return on equity of 22.99%. Who are Aurinia Pharmaceuticals' major shareholders? Aurinia Pharmaceuticals' top institutional shareholders include IFP Advisors Inc (0.28%), CWA Asset Management Group LLC (0.16%), Commonwealth Equity Services LLC (0.06%) and Juncture Wealth Strategies LLC (0.02%). Insiders that own company stock include Kevin Tang, Peter Greenleaf, Matthew Maxwell Donley, Joseph M Miller, Scott Michael Habig, Greg Keenan and Jeffrey Allen Bailey. View institutional ownership trends. How do I buy shares of Aurinia Pharmaceuticals? Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aurinia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aurinia Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Palantir Technologies (PLTR), Tesla (TSLA), Block (XYZ) and Exelixis (EXEL). Company Calendar Last Earnings10/30/2026Today11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 AUPH's financial health is in the Green zone, according to TradeSmith. AUPH has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AUPH CIK1600620 Webwww.auriniapharma.com Phone250-708-4272Fax250-744-2498Employees128Year Founded2013Price Target and Rating Average Price Target for Aurinia Pharmaceuticals$18.25 High Price Target$21.00 Low Price Target$16.00 Potential Upside/Downside+10.2%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$2.29 Trailing P/E Ratio7.23 Forward P/E Ratio15.92 P/E GrowthN/ANet Income$287.20 million Net Margins97.68% Pretax Margin51.94% Return on Equity22.99% Return on Assets17.99% Debt Debt-to-Equity Ratio0.06 Current Ratio6.12 Quick Ratio4.97 Sales & Book Value Annual Sales$283.05 million Price / Sales7.84 Cash Flow$1.04 per share Price / Cash Flow15.93 Book Value$4.91 per share Price / Book3.37Miscellaneous Outstanding Shares134,000,000Free Float119,214,000Market Cap$2.22 billion OptionableOptionable Beta1.40 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:AUPH) was last updated on 11/3/2026 by MarketBeat.com Staff. From Our PartnersFinancial Legend: “Big trouble ahead …”Dr. Martin D. Weiss, founder of Weiss Ratings and a two-time Congressional witness on financial institution ri...Weiss Ratings | SponsoredU.S. Army Advances 75-Year Rare Earth Deal With Nasdaq FirmThe Pentagon is moving to cut US dependence on Chinese rare earth metals, and a Nasdaq-listed company just sig...The Tomorrow Investor | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times th...Behind the Markets | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurinia Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
